The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma

by Giovanni Luca Gravina, Andrea Mancini, Francesco Marampon, Alessandro Colapietro, Simona Delle Monache, Roberta Sferra, Flora Vitale, Peter J. Richardson, Lee Patient, Stephen Burbidge, Claudio Festuccia
Published 2017-01-01

The novel CXCR4 antagonist, PRX177561, reduces tumor cell proliferation and accelerates cancer stem cell differentiation in glioblastoma preclinical models

by Giovanni Luca Gravina, Andrea Mancini, Alessandro Colapietro, Flora Vitale, Antonella Vetuschi, Simona Pompili, Giulia Rossi, Francesco Marampon, Peter J Richardson, Lee Patient, Lee Patient, Stephen Burbidge, Claudio Festuccia
Published 2017-06-01

Mechanism of baricitinib supports artificial intelligence‐predicted testing in COVID‐19 patients

by Justin Stebbing, Venkatesh Krishnan, Stephanie deBono, Silvia Ottaviani, Giacomo Casalini, Peter J Richardson, Vanessa Monteil, Volker M Lauschke, Ali Mirazimi, Sonia Youhanna, Yee‐Joo Tan, Fausto Baldanti, Antonella Sarasini, Jorge A Ross Terres, Brian J Nickoloff, Richard E Higgs, Guilherme Rocha, Nicole L Byers, Douglas E Schlichting, Ajay Nirula, Anabela Cardoso, Mario Corbellino, the Sacco Baricitinib Study Group
Published 2020-08-01